Iambic, a San Diego startup, said its physics‑informed algorithms and automated chemistry platforms can deliver small molecules from design to clinic in roughly two years. The company highlighted partnerships and early clinical entrants as validation for its approach, which couples AI-driven design with automated synthesis and testing. The model aims to shorten lead timelines and attract collaborators seeking faster preclinical-to-clinic transitions.